<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Labetalol: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Labetalol: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Labetalol: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="10785" href="/d/html/10785.html" rel="external">see "Labetalol: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13403" href="/d/html/13403.html" rel="external">see "Labetalol: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52867304"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Labetalol;</li>
<li>RIVA-Labetalol;</li>
<li>Trandate</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F186247"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antihypertensive;</li>
<li>
                        Beta-Blocker With Alpha-Blocking Activity</li></ul></div>
<div class="block doa drugH1Div" id="F186209"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Accumulation can occur with high-dose continuous infusions and may result in severe hypotension and bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18505576']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18505576'])">Ref</a></span>). There is limited documentation of prolonged continuous infusions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3415804','lexi-content-ref-7116758','lexi-content-ref-3723159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3415804','lexi-content-ref-7116758','lexi-content-ref-3723159'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f7069f2f-716f-4539-aa40-39abab340257">Acute aortic syndromes/acute aortic dissection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute aortic syndromes/acute aortic dissection (alternative agent)</b>
<b>(off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Manage patients on an emergency basis (including operative assessment) by first controlling pain with IV opioids and heart rate (target 60 to 80 beats per minute) with a parenteral beta blocker (eg, labetalol) while targeting systolic BP of ≤120 mm Hg (or lowest tolerated pressure without compromising perfusion). If systolic BP remains elevated after heart rate is controlled at 60 to 80 beats per minute with beta-blockade, may consider adding an additional parenteral vasodilator (ie, nitroprusside or nicardipine). Invasive BP monitoring, preferably via arterial line, in a critical care unit is recommended for appropriate dose titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-36322642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-36322642'])">Ref</a></span>). Although manufacturer's labeling recommends against exceeding a cumulative IV dose of 300 mg, it may be reasonable to exceed this dose in select patients, while monitoring for accumulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2316229']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2316229'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intermittent IV:</b> Initial: 20 mg over 2 minutes followed by 20 to 80 mg every 10 minutes until target heart rate and BP are reached; may transition to continuous infusion if unable to obtain target goals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-6310529','lexi-content-ref-21986463','lexi-content-ref-21908132','lexi-content-ref-22667825']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-6310529','lexi-content-ref-21986463','lexi-content-ref-21908132','lexi-content-ref-22667825'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous IV infusion:</b> Initial loading dose: 20 mg over 2 minutes (optional if intermittent dosing is used), followed by 0.5 to 2 mg/minute; some patients may require titration up to 10 mg/minute for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-21986463','lexi-content-ref-17565029','lexi-content-ref-31693807','lexi-content-ref-22667825']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-21986463','lexi-content-ref-17565029','lexi-content-ref-31693807','lexi-content-ref-22667825'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c4321da4-681e-4b90-ad74-21ac966a29fd">Acute ischemic stroke, BP management with reperfusion therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute ischemic stroke, BP management with reperfusion therapy (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Prior to reperfusion therapy (thrombolytic and/or mechanical thrombectomy), maintain a target BP of <b>≤185/110 mm Hg.</b> If BP remains &gt;185/110 mm Hg, do <b>not</b> administer thrombolytic. During and 24 hours after start of thrombolytic therapy, maintain a target BP of <b>≤180/105 mm Hg</b>; if hypertension is refractory or diastolic BP &gt;140 mm Hg, consider alternative therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31662037']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31662037'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Prior to reperfusion therapy:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 10 to 20 mg over 1 to 2 minutes; may repeat once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31662037']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31662037'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>During and after reperfusion therapy:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 10 mg over 1 to 2 minutes, followed by 2 to 8 mg/minute continuous infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31662037']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31662037'])">Ref</a></span>). Although manufacturer's labeling recommends against exceeding a cumulative IV dose of 300 mg, it may be reasonable to exceed this dose in select patients, while monitoring for accumulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2316229']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2316229'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a8a4567b-c11f-4e8d-a4cc-1bade3e801e9">Hypertension, acute/severe inpatient</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, acute/severe inpatient (including perioperative hypertension): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> The benefit of using IV antihypertensive agents to treat acute severe asymptomatic hypertension is not well established; in general, address underlying causes (eg, pain, agitation, withdrawal, hypervolemia) prior to initiating antihypertensive therapy. Rapid or excessive blood pressure reduction may be associated with severe adverse effects (eg, cerebral or myocardial ischemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26362300','lexi-content-ref-31705851','lexi-content-ref-Varon.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26362300','lexi-content-ref-31705851','lexi-content-ref-Varon.2019'])">Ref</a></span>). For patients with chronic hypertension prior to surgery, restart oral therapies as soon as appropriate once hemodynamically stable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bisognano.2019','lexi-content-ref-22864917']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bisognano.2019','lexi-content-ref-22864917'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intermittent IV:</b> Initial: 5 to 20 mg over 2 minutes; repeat dose every 10 minutes until target blood pressure is reached (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bisognano.2019','lexi-content-ref-London.2022','lexi-content-ref-6310529','lexi-content-ref-Mann.2020','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bisognano.2019','lexi-content-ref-London.2022','lexi-content-ref-6310529','lexi-content-ref-Mann.2020','lexi-content-ref-Manu.1'])">Ref</a></span>). Although manufacturer's labeling recommends against exceeding a cumulative IV dose of 300 mg, it may be reasonable to exceed this dose in selected patients, while monitoring for accumulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2316229']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2316229'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a79edee5-e147-4dcd-a540-d46e77df95f5">Hypertension, chronic/resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic/resistant:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Not recommended for initial management of hypertension, but may be considered as additional therapy in patients who do not respond adequately to combination therapy with preferred agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 100 mg twice daily; may increase as needed every 2 to 3 days by 100 mg twice daily (titration increments not to exceed 200 mg twice daily) until desired response is obtained; usual dosage range: 200 to 800 mg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>). In patients with resistant hypertension, doses up to 1.2 to 2.4 g/day in 2 or 3 divided doses may be required; however, combination therapy is preferred over dose escalation beyond the usual dosage range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-Brook.2020','lexi-content-ref-6310529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-Brook.2020','lexi-content-ref-6310529'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a669e060-0890-4fb4-a8f4-02d01c746a9b">Hypertensive emergency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertensive emergency: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>In general, reduce mean arterial blood pressure gradually by ~10% to 20% over the first hour, then by an additional 5% to 15% over the next 23 hours, unless there is a compelling indication (eg, acute aortic dissection, severe preeclampsia, eclampsia) for more rapid blood pressure and heart rate control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-Elliott.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-Elliott.2'])">Ref</a></span>). Although manufacturer's labeling recommends against exceeding a cumulative IV dose of 300 mg, it may be reasonable to exceed this dose in select patients, while monitoring for accumulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2316229']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2316229'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intermittent IV:</b> Initial: 10 to 20 mg over 1 to 2 minutes followed by 20 to 80 mg every 10 minutes until target blood pressure is reached; consider a continuous infusion if unable to obtain target blood pressure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-23535700','lexi-content-ref-Elliott.1','lexi-content-ref-6310529','lexi-content-ref-21986463','lexi-content-ref-21908132','lexi-content-ref-22667825']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-23535700','lexi-content-ref-Elliott.1','lexi-content-ref-6310529','lexi-content-ref-21986463','lexi-content-ref-21908132','lexi-content-ref-22667825'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous IV infusion:</b> Initial loading dose: 10 to 20 mg over 2 minutes (optional if intermittent dosing is used), followed by 0.5 to 2 mg/minute; some patients may require titration up to 10 mg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-21986463','lexi-content-ref-17565029','lexi-content-ref-31693807','lexi-content-ref-22667825']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-21986463','lexi-content-ref-17565029','lexi-content-ref-31693807','lexi-content-ref-22667825'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e9f708dd-ef5e-4e74-8eb4-bbad8f556048">Hypertensive emergency in pregnancy or postpartum</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertensive emergency in pregnancy or postpartum (including acute-onset severe hypertension in preeclampsia/eclampsia) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For acute-onset, severe, persistent hypertension (eg, systolic BP ≥160 mm Hg or diastolic BP ≥110 mm Hg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32443079']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32443079'])">Ref</a></span>). Although manufacturer's labeling recommends against exceeding a cumulative IV dose of 300 mg, it may be reasonable to exceed this dose in selected patients, while monitoring for accumulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2316229']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2316229'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intermittent IV:</b> Initial: 20 mg over 2 minutes; if blood pressure exceeds thresholds after 10 to 30 minutes, increase dose in increments of 20 to 40 mg every 10 to 30 minutes; maximum single dose: 80 mg. <b>Note:</b> If blood pressures remain above threshold after several intermittent doses, another agent should be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32443079','lexi-content-ref-August.2022','lexi-content-ref-35577426']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32443079','lexi-content-ref-August.2022','lexi-content-ref-35577426'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous IV infusion:</b> Initial loading dose: 20 mg over 2 minutes (optional if intermittent dosing is used), followed by 0.5 to 2 mg/minute titrated to response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32443079','lexi-content-ref-August.2022','lexi-content-ref-35577426']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32443079','lexi-content-ref-August.2022','lexi-content-ref-35577426'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral (alternative route):</b> Initial: 200 mg every 60 minutes for up to 3 doses. <b>Note: </b>May use as alternative route to other ineffective oral therapy; IV therapy (intermittent or continuous infusion) may be needed for more acute treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35577426']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35577426'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="31b3d7ad-f085-452f-a832-866c94a87948">Intracerebral hemorrhage, acute, blood pressure management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intracerebral hemorrhage, acute, blood pressure management (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use in patients with mild to moderate intracerebral hemorrhage with a presenting systolic BP ≥150 mm Hg; acute lowering to &lt;130 mm Hg is potentially harmful (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35579034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35579034'])">Ref</a></span>). Although manufacturer's labeling recommends against exceeding a cumulative IV dose of 300 mg, it may be reasonable to exceed this dose in select patients, while monitoring for accumulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2316229']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2316229'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Patients who present with systolic BP 150 to 220 mm Hg:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Intermittent IV:</b> Initial: 5 to 20 mg IV push over 2 minutes. May repeat every 10 to 15 minutes; repeat doses may be increased incrementally up to 80 mg as needed based on response and tolerability until target systolic BP is reached; may consider a continuous infusion if unable to obtain target goals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17478736','lexi-content-ref-35579034','lexi-content-ref-Rordorf.2022','lexi-content-ref-16174926','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17478736','lexi-content-ref-35579034','lexi-content-ref-Rordorf.2022','lexi-content-ref-16174926','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Patients who present with systolic BP &gt;220 mm Hg (alternative agent):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Continuous IV infusion:</b> Initial loading dose: 20 mg over 2 minutes, followed by 0.5 to 2 mg/minute; titrate to target systolic BP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17478736','lexi-content-ref-17967691','lexi-content-ref-23055089','lexi-content-ref-Rordorf.2022','lexi-content-ref-16174926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17478736','lexi-content-ref-17967691','lexi-content-ref-23055089','lexi-content-ref-Rordorf.2022','lexi-content-ref-16174926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0e395518-1fe9-4e98-b264-8cef989eaea2">Subarachnoid hemorrhage, blood pressure management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Subarachnoid hemorrhage, blood pressure management (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Optimal therapy is not well established. Cautious use of antihypertensive therapy to decrease the risk of rebleeding may be appropriate in some patients with systolic BP &gt;160 mm Hg or mean arterial pressure &gt;110 mm Hg with adequate cerebral perfusion pressures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22556195','lexi-content-ref-Singer.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22556195','lexi-content-ref-Singer.2022'])">Ref</a></span>). Although manufacturer's labeling recommends against exceeding a cumulative IV dose of 300 mg, it may be reasonable to exceed this dose in selected patients, while monitoring for accumulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2316229']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2316229'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intermittent IV:</b> Initial: 10 to 20 mg over 2 minutes; followed by 20 to 80 mg every 10 to 15 minutes until systolic BP &lt;160 mm Hg or mean arterial pressure &lt;100 mm Hg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23760911','lexi-content-ref-17967691','lexi-content-ref-8439694','lexi-content-ref-22528277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23760911','lexi-content-ref-17967691','lexi-content-ref-8439694','lexi-content-ref-22528277'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous IV infusion:</b> 0.5 to 2 mg/minute titrated to response; based on very limited data (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17967691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17967691'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>
<b>IV to oral conversion:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">Upon discontinuation of continuous IV infusion, may initiate oral dose of 200 mg followed in 6 to 12 hours with an additional dose of 200 to 400 mg; adjust dose based on response at ≥1-day intervals to a range of 400 mg/day to 2.4 g/day in 2 to 3 divided doses. <b>Note:</b> For hypertension, the usual dosage range is 200 to 800 mg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990649"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV, Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b> Mild to severe impairment<b>:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6961760','lexi-content-ref-7093103']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6961760','lexi-content-ref-7093103'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Poorly dialyzed (manufacturer’s labeling); no supplemental dose or dosage adjustment necessary (expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Poorly dialyzed (manufacturer’s labeling); no dosage adjustment necessary (expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b> No dosage adjustment necessary (expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (expert opinion).</p></div>
<div class="block doha drugH1Div" id="F50987859"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. However, dosage reduction may be necessary in hepatic impairment due to decreased metabolism and increased oral bioavailability, use with caution.</p></div>
<div class="block doe drugH1Div" id="F186210"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension:</b>
<i>Oral:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Manufacturer's labeling: Initial: 100 mg twice daily; may titrate in increments of 100 mg twice daily; usual maintenance: 100 to 200 mg twice daily</p>
<p style="text-indent:-2em;margin-left:4em;">ACCF/AHA Expert Consensus recommendations: Consider lower initial doses and titrating to response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21518977']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21518977'])">Ref</a></span>)</p></div>
<div class="block dop drugH1Div" id="F186227"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13403" href="/d/html/13403.html" rel="external">see "Labetalol: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Use care with labetalol continuous IV infusions; the rate of administration is different for pediatric patients (mg/kg/hour) versus adult patients (mg/minute).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acute severe hypertension with life-threatening symptoms</i>: Limited data available:</p>
<p style="text-indent:-2em;margin-left:8em;">IV (intermittent bolus): Children and Adolescents: 0.2 to 1 mg/kg/dose; maximum dose: 40 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28827377','lexi-content-ref-1731011','lexi-content-ref-18839219']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28827377','lexi-content-ref-1731011','lexi-content-ref-18839219'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Continuous IV infusion: Infants, Children, and Adolescents: 0.25 to 3 mg/kg/<b>hour</b>; initiate at lower end of range and titrate up slowly to effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28827377','lexi-content-ref-1731011','lexi-content-ref-18839219','lexi-content-ref-20495503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28827377','lexi-content-ref-1731011','lexi-content-ref-18839219','lexi-content-ref-20495503'])">Ref</a></span>). In one retrospective study in infants and children ≤24 months of age, reductions in blood pressure were observed at doses up to 0.59 mg/kg/hour, with little additional benefit at higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20495503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20495503'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic hypertension: </i>Limited data available: Children and Adolescents: Oral: Initial: 1 to 3 mg/kg/<b>day</b> in 2 divided doses; maximum daily dose: 10 to 12 mg/kg/<b>day</b>, up to 1,200 mg<b>/day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NHLBI.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NHLBI.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51114940"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. &lt;1% removed by hemo- or peritoneal dialysis.</p></div>
<div class="block dohp drugH1Div" id="F51114941"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; however, dosage reduction may be necessary in hepatic impairment due to decreased metabolism and increased oral bioavailability; use with caution.</p></div>
<div class="block arsc drugH1Div" id="F58595937"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bradyarrhythmias</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Beta-blockers may cause <b>bradycardia</b> and <b>heart block</b>, including first-degree atrioventricular (AV) block<b>, </b>second-degree AV block, or complete AV block (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36620804','lexi-content-ref-15288162','lexi-content-ref-22300487','lexi-content-ref-15234417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36620804','lexi-content-ref-15288162','lexi-content-ref-22300487','lexi-content-ref-15234417'])">Ref</a></span>). At maintenance dosing, second- or third-degree AV block are less likely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2450898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2450898'])">Ref</a></span>). Beta-blocking agents with intrinsic sympathomimetic activity (ISA) (eg, pindolol) may cause fewer AV conduction abnormalities than those without intrinsic sympathomimetic activity (eg, carvedilol) due to their partial agonist effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2892986','lexi-content-ref-1977302','lexi-content-ref-2450898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2892986','lexi-content-ref-1977302','lexi-content-ref-2450898'])">Ref</a></span>); labetalol possesses a very small degree of ISA and exhibits a slight, but irregular effect on AV conduction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7308279','lexi-content-ref-6310529','lexi-content-ref-2450898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7308279','lexi-content-ref-6310529','lexi-content-ref-2450898'])">Ref</a></span>). In most cases (up to 72%), AV block associated with a beta-blocker will resolve upon discontinuation; however, there are reported cases of recurrent AV block and nearly 50% of patients with more severe AV block may require a permanent pacemaker (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22530749']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22530749'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Blockade of cardiac beta-1 adrenergic receptors results in slowed conduction and prolongation of the refractory period of the AV node. Slowing of AV conduction can lead to AV block (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15288162','lexi-content-ref-2450898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15288162','lexi-content-ref-2450898'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; one study included patients who were on a beta-blocker for more than 1 month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27899939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27899939'])">Ref</a></span>); however, other studies noted prolongation AV nodal refractory period occurring anywhere from 1 dose to several days following treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7308279','lexi-content-ref-30753292','lexi-content-ref-2450898','lexi-content-ref-6608433']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7308279','lexi-content-ref-30753292','lexi-content-ref-2450898','lexi-content-ref-6608433'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Impaired AV node conduction or sinus node function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15288162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15288162'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other agents that impair AV nodal conduction (eg, nondihydropyridine calcium channel blockers, digoxin, ivabradine, select antiarrhythmic agents) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27899939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27899939'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27899939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27899939'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bronchospasm</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Nonselective beta-blockers (eg, labetalol) have a higher risk of <b>bronchospasm</b> compared to cardioselective beta-blockers and may lead to drug discontinuation in patients with chronic obstructive pulmonary diseases (COPD) or asthma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29066880','lexi-content-ref-27390282','lexi-content-ref-24202435','lexi-content-ref-31352857']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29066880','lexi-content-ref-27390282','lexi-content-ref-24202435','lexi-content-ref-31352857'])">Ref</a></span>). Use of labetalol in patients with hypertension and COPD or asthma has been associated with varying degrees of impact on FEV<sub>1</sub>, forced expiratory flow, and/or forced vital capacity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6184571','lexi-content-ref-6337786','lexi-content-ref-3905285']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6184571','lexi-content-ref-6337786','lexi-content-ref-3905285'])">Ref</a></span>). Based on the use of other beta-blockers in this setting, concurrent use of inhaled bronchodilators and/or corticosteroids are protective against beta-blocker-induced bronchospasm in patients with COPD or asthma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12490274','lexi-content-ref-27390282','lexi-content-ref-28840400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12490274','lexi-content-ref-27390282','lexi-content-ref-28840400'])">Ref</a></span>). Bronchospasm is reversible upon discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2439802']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2439802'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to pharmacologic action. Beta-blocking agents can lead to airway smooth muscle constriction by antagonism of beta-2 receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15579370','lexi-content-ref-27390282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15579370','lexi-content-ref-27390282'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; changes in pulmonary function tests have occurred after 1 dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3905285']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3905285'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Reactive airway disease (asthma) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12490274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12490274'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Beta-blockers may cause CNS effects such as <b>fatigue</b>, sleep disorder, insomnia, and vivid dreams (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714','lexi-content-ref-12117400','lexi-content-ref-15288162','lexi-content-ref-1969642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714','lexi-content-ref-12117400','lexi-content-ref-15288162','lexi-content-ref-1969642'])">Ref</a></span>). Lipophilic beta-blockers (including labetalol) penetrate the blood-brain barrier to a greater extent than hydrophilic beta-blockers, possibly leading to a greater incidence of CNS effects; however, other studies have refuted this theory (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714','lexi-content-ref-1969642','lexi-content-ref-19724774','lexi-content-ref-2865153']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714','lexi-content-ref-1969642','lexi-content-ref-19724774','lexi-content-ref-2865153'])">Ref</a></span>). Sexual disorders may occur; however, patients who require beta-blocker therapy have risk factors for erectile dysfunction (eg, coronary artery disease, heart failure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Botros.1','lexi-content-ref-29746858','lexi-content-ref-12117400','lexi-content-ref-3339748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Botros.1','lexi-content-ref-29746858','lexi-content-ref-12117400','lexi-content-ref-3339748'])">Ref</a></span>). Memory impairment has been reported with the use of other lipophilic beta-blockers (eg, carvedilol); however newer data suggests carvedilol may be helpful for patients with Alzheimer disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17534003','lexi-content-ref-20579773']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17534003','lexi-content-ref-20579773'])">Ref</a></span>). CNS effects generally resolve with dose reduction or discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; exact mechanism is not fully understood. Proposed mechanisms include presence of beta receptors in the brain, affinity and in some instances, inhibition of beta-blocking agents towards serotonin (5-HT) receptors in the brain (affecting mood and sleep), and beta-blocker-induced decreases in central sympathetic output (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8956349','lexi-content-ref-2865151','lexi-content-ref-2878741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8956349','lexi-content-ref-2865151','lexi-content-ref-2878741'])">Ref</a></span>). Beta-1 blockade may also impact sleep by blocking sympathetic signaling to the pineal gland, resulting in suppression of nighttime levels of melatonin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23024438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23024438'])">Ref</a></span>). Beta-blockers may cause erectile dysfunction through decreased sympathetic nervous system output and subsequent decreases in luteinizing hormone secretion and testosterone stimulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24155101']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24155101'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; CNS effects often occur within the first few weeks of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher starting doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969642'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Potentiation/masking of hypoglycemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Beta-blockers may worsen, prolong, or cause hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2861072','lexi-content-ref-Vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2861072','lexi-content-ref-Vue.1'])">Ref</a></span>). Additionally, beta-blockers may mask symptoms of hypoglycemia (tremor, irritability, palpitations), making diaphoresis the only symptom unaffected by beta-blockers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vue.1'])">Ref</a></span>). It is unclear if nonselective or selective beta-blockers are more likely to cause hypoglycemia; as data are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15536109','lexi-content-ref-31775749','lexi-content-ref-20067434','lexi-content-ref-85053','lexi-content-ref-6376017','lexi-content-ref-9207336','lexi-content-ref-Vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15536109','lexi-content-ref-31775749','lexi-content-ref-20067434','lexi-content-ref-85053','lexi-content-ref-6376017','lexi-content-ref-9207336','lexi-content-ref-Vue.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Beta-blockers inhibit hepatic gluconeogenesis and glycogenolysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2861072','lexi-content-ref-Vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2861072','lexi-content-ref-Vue.1'])">Ref</a></span>). Beta-blockers also reduce activation of the sympathetic nervous system, therefore masking hypoglycemic symptoms that are catecholamine-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vue.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; hypoglycemia (&lt;70 mg/dL) was reported significantly more after 24 hours of nonselective beta-blocker (ie, carvedilol) use compared to patients not on beta-blockers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31775749']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31775749'])">Ref</a></span>). In another study, episodes of severe hypoglycemia (&lt;50 mg/dL) were reported over the course of 4 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28559400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28559400'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Insulin-dependent diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2861072']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2861072'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Type 2 diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28559400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28559400'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients who are hospitalized and not requiring basal insulin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31775749']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31775749'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Beta-blocker therapy should not be withdrawn abruptly, but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia in patients with underlying cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2897781','lexi-content-ref-2883874','lexi-content-ref-37093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2897781','lexi-content-ref-2883874','lexi-content-ref-37093'])">Ref</a></span>). Some studies have found an increase in propensity-adjusted mortality and cardiovascular events; however, one study did not find changes in infarct size and left ventricular function when beta-blocker was abruptly withdrawn in patients with myocardial infarction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3009050','lexi-content-ref-18617067','lexi-content-ref-1968518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3009050','lexi-content-ref-18617067','lexi-content-ref-1968518'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-dependent; related to the pharmacologic action. Beta blockade causes upregulation of beta-receptors, enhanced receptor sensitivity, and decreased sympathetic nervous system response. Abrupt withdrawal leads to a transient sympathetic hyper-response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2883874','lexi-content-ref-37093','lexi-content-ref-6125186','lexi-content-ref-6125187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2883874','lexi-content-ref-37093','lexi-content-ref-6125186','lexi-content-ref-6125187'])">Ref</a></span>). Another proposed mechanism involves increased platelet aggregability to epinephrine and thrombin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2883874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2883874'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid/varied and transient; increases in heart rate and blood pressure appear 24 hours after abrupt withdrawal, peak after 48 hours, and subside after 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37093'])">Ref</a></span>). In other nonselective beta-blockers (propranolol), anginal symptoms reported to begin 12 to 24 hours after discontinuation. Development of adverse reactions also reported to occur 1 to 21 days after withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2897781','lexi-content-ref-1244260','lexi-content-ref-668066']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2897781','lexi-content-ref-1244260','lexi-content-ref-668066'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt withdrawal in chronic users (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37093'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Past medical history of coronary artery disease (including chronic stable angina) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2897781','lexi-content-ref-2883874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2897781','lexi-content-ref-2883874'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Past medical history of hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37093','lexi-content-ref-1968518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37093','lexi-content-ref-1968518'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F186167"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Orthostatic hypotension (IV: 58%; oral: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (≤19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (1% to 16%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (oral: 1% to 2%), flushing (IV: 1%), hypotension (IV: 1%), ventricular arrhythmia (IV: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (IV: 4%; oral: &lt;1%), pruritus (IV: 1%), skin rash (oral: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (1%), dyspepsia (IV: 1%; oral: 1% to 4%), vomiting (oral: ≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Ejaculatory failure (oral: 1% to 5%), impotence (oral: 1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (oral: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness (IV: ≤3%), fatigue (oral: 1% to 10%)<span class="lexi-table-link-container"> (<a aria-label="Fatigue table link" class="lexi-table-link" data-table-id="lexi-content-fatigue" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fatigue')">table 1</a>)</span><span class="table-link" style="display:none;">Fatigue</span>, headache (oral: 2%), hypoesthesia (IV: 1%), paresthesia (≤7%), vertigo (1% to 2%), yawning (IV: ≤3%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Fatigue" frame="border" id="lexi-content-fatigue" rules="all">
<caption style="text-align:center;">
<b>Labetalol: Adverse Reaction: Fatigue</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Labetalol)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Propranolol)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Metoprolol)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Labetalol)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Propranolol)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Metoprolol)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,400 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">175</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,200 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">411</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,600 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">242</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">227</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">84</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">49</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">800 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">503</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">400 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">606</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">608</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">900 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">117</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">522</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">181</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance (oral: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen (≤8%), increased serum creatinine (IV: 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (oral: 2%), nasal congestion (oral: 1% to 6%), wheezing (IV: 1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Gastrointestinal: Diarrhea</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, heart block, heart failure, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Facial erythema, lichen planus (bullous), lichenoid eruption, maculopapular rash, psoriasiform eruption, transient alopecia, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Acute urinary retention, difficulty in micturition, Peyronie disease</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Positive ANA titer</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic jaundice, hepatic injury, hepatic necrosis, hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, hypersensitivity reaction, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (antimitochondrial)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle cramps, myopathy (Willis 1990), systemic lupus erythematosus</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Dry eye syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F186184"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to labetalol or any component of the formulation; severe bradycardia; heart block greater than first degree (except in patients with a functioning artificial pacemaker); cardiogenic shock; bronchial asthma or a history of obstructive airway disease; uncompensated cardiac failure; conditions associated with severe and prolonged hypotension</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Sick sinus syndrome (except in patients with a functioning artificial pacemaker); state of hypoperfusion; severe peripheral arterial circulatory disorders.</p></div>
<div class="block war drugH1Div" id="F186164"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.</p>
<p style="text-indent:-2em;margin-left:4em;">• Floppy iris syndrome: Intraoperative floppy iris syndrome has been observed in cataract surgery patients who were treated with alpha<sub>1</sub>-blockers. There appears to be no benefit in discontinuing alpha-blocker therapy prior to surgery.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic injury: Severe hepatocellular injury has been reported (rare). The hepatic injury is usually reversible, but hepatic necrosis and death have been reported. Injury has occurred after both short- and long-term treatment and may be slowly progressive despite minimal symptomatology.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure (HF): Use with extreme caution in patients with compensated heart failure and monitor for a worsening of the condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; bioavailability is increased due to decreased first-pass metabolism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use beta blockers with caution in patients with myasthenia gravis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peripheral vascular disease (PVD) and Raynaud disease: Beta blockers may precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud disease; use with caution and monitor for progression of arterial obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pheochromocytoma: Labetalol may be effective in lowering blood pressure and relieving symptoms in patients with pheochromocytoma; however, patients may experience paradoxical hypertensive responses due to inadequate alpha-1 blockade (Manger 2002; Mazza 2014). Adequate alpha-1 blockade should be initiated prior to use of any beta-blocker in this setting; use with caution in patients with pheochromocytoma or consider alternative therapy. If possible, obtain diagnostic tests for pheochromocytoma prior to use since labetalol may spuriously cause falsely elevated levels of plasma catecholamine and urinary metanephrine (Bravo 2002; MacCarthy 1983).</p>
<p style="text-indent:-2em;margin-left:4em;">• Psoriasis: Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: Beta blockers may mask signs of hyperthyroidism (eg, tachycardia). If hyperthyroidism is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.</p></div>
<div class="block foc drugH1Div" id="F186176"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/mL (4 mL, 20 mL, 40 mL); 100 mg/100 mL (1 mg/mL) with NaCl 0.72% (100 mL); 200 mg/200 mL (1 mg/mL) with NaCl 0.72% (200 mL); 200 mg/200 mL (1 mg/mL) with dextrose 5% (200 mL); 300 mg/300 mL (1 mg/mL) in NaCl 0.72% (300 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/2 mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 200 mg, 300 mg</p></div>
<div class="block geq drugH1Div" id="F186160"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F186186"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Labetalol HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/mL (per mL): $0.13 - $0.69</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Labetalol HCl-Dextrose Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/200 mL 5% (per mL): $0.17</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Labetalol HCl-Sodium Chloride Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100MG/100ML 0.72% (per mL): $0.17</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200MG/200ML 0.72% (per mL): $0.17</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300MG/300ML 0.72% (per mL): $0.17</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Labetalol HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/2 mL (per mL): $3.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Labetalol HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.17 - $0.67</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $0.26 - $1.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $0.35 - $1.15</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867305"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/mL (20 mL, 40 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trandate: 100 mg [contains sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trandate: 200 mg [contains fd&amp;c yellow #6 (sunset yellow), sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 200 mg</p></div>
<div class="block adm drugH1Div" id="F186180"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer without regard to food; however, the absolute bioavailability of labetalol is increased when administered with food. Administer in a consistent manner with regards to meals.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral:</b> Bolus dose of 10 mg may be administered IV push at a rate of 10 mg/minute; bolus doses of ≥20 mg may be administered IV push over 2 minutes; may follow with continuous IV infusion if clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACOG.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACOG.1','lexi-content-ref-Manu.1'])">Ref</a></span>). Orthostatic hypotension may occur with IV administration; patient should remain supine during and for up to 3 hours after IV administration; patient’s ability to tolerate an upright position should be established before permitting ambulation or assuming an upright position.</p></div>
<div class="block admp drugH1Div" id="F52613116"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer without regard to food; however, the absolute bioavailability of labetalol is increased when administered with food. Administer in a consistent manner with regards to meals.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IV bolus: Based on adult information, may administer undiluted over 2 minutes; maximum: 10 mg/minute.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Administer as a continuous IV infusion with the use of an infusion pump.</p></div>
<div class="block uica drugH1Div" id="F14472668"><span class="drugH1">Usual Infusion Concentrations: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Premixed solutions are available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV infusion:</b> 200 mg in 200 mL (concentration: 1 mg/mL) <b>or</b> 400 mg in 200 mL (concentration: 2 mg/mL) <b>or</b> 500 mg in 250 mL (concentration: 2 mg/mL) of D5W.</p></div>
<div class="block uicp drugH1Div" id="F14472669"><span class="drugH1">Usual Infusion Concentrations: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>IV infusion:</b> 1 mg/mL, 5 mg/mL.</p></div>
<div class="block use drugH1Div" id="F186179"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Hypertension:</b> Management of hypertension (IV indicated for severe hypertension only [eg, hypertensive emergencies]). <b>Note:</b> Beta-blockers are <b>not</b> recommended as first-line therapy (ACC/AHA [Whelton 2018]).</p></div>
<div class="block off-label drugH1Div" id="F25726710"><span class="drugH1">Use: Off-Label: Adult</span><p>Acute aortic syndromes/Acute aortic dissection; Acute ischemic stroke, BP management with reperfusion therapy; Hypertensive emergency in pregnancy or postpartum (including acute-onset severe hypertension in preeclampsia/eclampsia); Intracerebral hemorrhage, acute, blood pressure management; Subarachnoid hemorrhage, blood pressure management</p></div>
<div class="block mst drugH1Div" id="F186256"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Labetalol may be confused with betaxolol, LaMICtal, lamoTRIgine, Lipitor</p>
<p style="text-indent:-2em;margin-left:4em;">Normodyne may be confused with Norpramin</p>
<p style="text-indent:-2em;margin-left:4em;">Trandate may be confused with traMADol, Trental</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (IV formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Significant differences exist between oral and IV dosing. Use caution when converting from one route of administration to another.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299562"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F186169"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Beta-Blockers (Nonselective) may enhance the hypoglycemic effect of Antidiabetic Agents. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: Beta-Blockers may enhance the adverse/toxic effect of Cannabis. Specifically, the risk of hypoglycemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may enhance the negative inotropic effect of Disopyramide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOBUTamine: Beta-Blockers may diminish the therapeutic effect of DOBUTamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose. Increase monitoring for clinical response and adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPHEDrine (Systemic): Beta-Blockers may diminish the therapeutic effect of EPHEDrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Nasal): Beta-Blockers (with Alpha-Blocking Properties) may diminish the therapeutic effect of EPINEPHrine (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Oral Inhalation): Beta-Blockers (with Alpha-Blocking Properties) may diminish the therapeutic effect of EPINEPHrine (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Epinephrine (Racemic): Beta-Blockers (with Alpha-Blocking Properties) may diminish the therapeutic effect of Epinephrine (Racemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Systemic): Beta-Blockers (with Alpha-Blocking Properties) may diminish the therapeutic effect of EPINEPHrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may diminish the therapeutic effect of Etilefrine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etofylline: Beta-Blockers may diminish the therapeutic effect of Etofylline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grass Pollen Allergen Extract (5 Grass Extract): Beta-Blockers may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). More specifically, Beta-Blockers may inhibit the ability to effectively treat severe allergic reactions to Grass Pollen Allergen Extract (5 Grass Extract) with epinephrine.  Some other effects of epinephrine may be unaffected or even enhanced (e.g., vasoconstriction) during treatment with Beta-Blockers.  Management: Consider alternatives to either grass pollen allergen extract (5 grass extract) or beta-blockers in patients with indications for both agents.  Canadian product labeling specifically lists this combination as contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Insulins: Beta-Blockers (Nonselective) may enhance the hypoglycemic effect of Insulins. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Insulins. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: Labetalol may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer labetalol until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoproterenol: Beta-Blockers may diminish the therapeutic effect of Isoproterenol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: Beta-Blockers may enhance the adverse/toxic effect of Mavacamten. Specifically, negative inotropic effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Beta-Blockers may enhance the therapeutic effect of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: May enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: May enhance the therapeutic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May diminish the therapeutic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reserpine: May enhance the bradycardic effect of Beta-Blockers. Reserpine may enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: May enhance the bradycardic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Beta-Blockers may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Beta-Blockers (Nonselective) may enhance the hypoglycemic effect of Sulfonylureas. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: Beta-Blockers may diminish the therapeutic effect of Tasimelteon.  Management: Consider avoiding nighttime administration of beta-blockers during tasimelteon therapy due to the potential for reduced tasimelteon efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">White Birch Allergen Extract: Beta-Blockers may enhance the adverse/toxic effect of White Birch Allergen Extract. Specifically, beta-blockers may reduce the effectiveness of beta-agonists that may be required to treat systemic reactions to white birch allergen extract. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F186200"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Labetalol serum concentrations may be increased if taken with food. Management: Administer with food.</p></div>
<div class="block rep_considerations drugH1Div" id="F56721575"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be continued in patients trying to conceive. Labetalol is one of the medications patients can transition to if currently taking an agent that is ineffective or should be avoided during pregnancy (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Erectile dysfunction and inhibition of sperm motility are noted in product labeling following use of beta-blockers, including labetalol. As a class, outcomes from available studies evaluating beta-blockers and sexual dysfunction are inconsistent, and the negative effects on erectile function are considered controversial. A clear relationship between use of beta-blockers and erectile dysfunction has not been established. Hypertension itself is associated with erectile dysfunction. Patients on a beta-blocker presenting with sexual dysfunction should be evaluated for underlying disease (Farmakis 2021; Levine 2012; Semet 2017; Terentes-Printzios 2022; Viigimaa 2020).</p></div>
<div class="block pri drugH1Div" id="F186187"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Labetalol crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Exposure to beta-blockers during pregnancy may increase the risk for adverse events in the neonate. If maternal use of a beta-blocker is needed, monitor fetal growth during pregnancy; monitor the newborn for 48 hours after delivery for bradycardia, hypoglycemia, and respiratory depression (ESC [Regitz-Zagrosek 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is also associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of labetalol may be altered (Mulrenin 2021; van de Vusse 2022). Dose adjustments may be required; close monitoring is recommended (Mulrenin 2021; SOGC [Magee 2022]).</p>
<p style="text-indent:0em;margin-top:2em;">Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). When treatment for hypertension is initiated during pregnancy, oral labetalol is one of the preferred agents (ACOG 2019; ESC [Cífková 2020]; ESC [Regitz-Zagrosek 2018]; SOGC [Magee 2022]). IV labetalol is recommended for use in the management of hypertensive emergencies in pregnant or postpartum patients (including acute-onset severe hypertension in preeclampsia/eclampsia) (ACOG 2020a; SOGC [Magee 2022]).</p></div>
<div class="block brc drugH1Div" id="F186188"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Labetalol is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of labetalol in breast milk are available following maternal administration of oral labetalol 300 mg twice daily to a woman for preeclampsia. Delivery was at 26 weeks' gestation; breast milk concentrations ~8 days postpartum were 0.71 mcg/mL (Mirpuri 2008). Using a milk concentration of 0.71 mcg/mL, the estimated daily infant dose via breast milk is 0.1065 mg/kg/day providing a relative infant dose (RID) of 3.6% compared to an infant therapeutic dose of 3 mg/kg/day. In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">Breast milk concentrations have not been found to correspond to maternal serum concentrations (Lunell 1985; Michael 1979). Peak breast milk concentrations are noted to occur 1 to 3 hours after the maternal dose (Lunell 1985).</p>
<p style="text-indent:-2em;margin-left:2em;">Asymptomatic bradycardia was observed in a preterm infant exclusively breastfed following maternal use of labetalol (Mirpuri 2008). Nipple pain and Raynaud phenomenon of the nipple has been associated with labetalol in case reports (Rolfes 2014).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Labetalol is considered compatible for use in patients who are breastfeeding (ACOG 2019; ESC [Cífková 2020]; SOGC [Magee 2022]).</p></div>
<div class="block mop drugH1Div" id="F186174"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">BP (especially with initial dosing and dosing increases), heart rate, continuous cardiac monitoring recommended for IV administration (consult individual institutional policies and procedures); periodic LFTs if clinically indicated; mental alertness; signs and symptoms of bronchospasm in patients with existing bronchospastic disease; serum glucose (in patients with diabetes).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, acute in pregnancy (hypertensive emergency/urgency):</b> Once target BP is achieved, monitor every 10 minutes for the first hour, then every 15 minutes for 1 hour, then every 30 minutes for 1 hour, then every hour for 4 hours (ACOG 2020b).</p></div>
<div class="block rer drugH1Div" id="F57878763"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">BP goal<b>:</b> May vary depending on clinical conditions, different clinical practice guidelines, and expert opinion. Refer to "Clinical Practice Guidelines" for specific treatment goals.</p></div>
<div class="block pha drugH1Div" id="F186163"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Blocks alpha<sub>1</sub>-, beta<sub>1</sub>-, and beta<sub>2</sub>-adrenergic receptor sites; elevated renins are reduced. The ratios of alpha- to beta-blockade differ depending on the route of administration estimated to be 1:3 (oral) and 1:7 (IV) (Goa 1989).</p></div>
<div class="block phk drugH1Div" id="F186183"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Oral: 20 minutes to 2 hours (McNeil 1984); IV: Within 5 minutes (Goa 1989)</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: Oral: 2 to 4 hours; IV: 5 to 15 minutes (Goa 1989)</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Blood pressure response:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: 8 to 12 hours (dose dependent)</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Average: 16 to 18 hours (dose dependent)</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Complete</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Apparent V<sub>d</sub>: Adults: 2.5 to 15.7 L/kg (Goa 1989)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~50%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic, primarily via glucuronide conjugation; extensive first-pass effect</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: 25%; increased with liver disease, elderly, and concurrent cimetidine</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Oral: 6 to 8 hours; IV: ~5.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Oral: 1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (55% to 60% as glucuronide conjugates, &lt;5% as unchanged drug [Goa 1989]); feces (12% to 27% as metabolites) (Goa 1989)</p></div>
<div class="block phksp drugH1Div" id="F51197828"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Elimination is reduced in elderly patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038665"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Biascor | Blocamine | Labetalol | Labetalol richet</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Trandate</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Labetalol sxp | Presolol | Trandate</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Labecard | Labegest | Labeta</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Trandate</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Trandate</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Trandate</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Labetalol</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Diblorec | Labetalol | Labetalol clorhidrato | Labetalol HCL | Presequil | Telabelol | Trandate</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Labetalol | Trandate</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Biascor | Diblorec</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Labetalolo s.a.l.f. | Trandate</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Labipress</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Trandate</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Albetol | Labetalol s.a.l.f | Trandate</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Labetalol Dci | Trandate</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Labetalol | Labetalol astec | Labetalol cox | Labetalol dc | Labetalol kent | Labetalol sandoz | Labrocol | Trandate</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Trandate</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Labetalol HCL | Trandate</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Trandate</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Trandate</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Trandate</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Trandate</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alphadopa l | Culol | Eubet | Evabet | Gravidol | Gynapres L | Labebet | Labepure | Labetamac | Labetol | Labil | Lablol | Lebatens | Lexol | Lobet | Lopih | Pregnasafe | Tiplab</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Amipress | Ipolab | Labetalolo s.a.l.f. | Trandate</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Amitalol | Ascool | Labestonin | Resporito | Trandate | Trandate glaxosmithkline | Trandate takeda</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Betasin | Labesin | Trandate</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Labetalol | Labetalol HCL | Trandate</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Coreton | Labetalol | Norbetol | Trandate | Trandate aspen</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Trandate</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Coreton | Trandate</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Labetalol | Labetalol pharmaniaga | Pharmaniaga labetalol hydrochloride | Tolbetol | Trandate | Trantalol</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Labetalol HCL</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Labetalol | Labetalol B-Medical | Labetalol HCL | Labetalol hcl Alpharma | Labetalol Hcl CF | Labetalol Hcl Katwijk | Labetalol Hcl Merck | Labetalol hcl PCH | Labetalol Hcl Sandoz | Trandate</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Labetalol bedford | Labetalol s.a.l.f | Trandate</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Hybloc | Labetalol | Presolol | Trandate</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Abetol</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Labetalol | Labetol | Letol</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Coreton | Labetalol HCL | Pressocard | Trandate</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Labetalol | Labetalol HCL | Normodyne | Trandate</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Labetalol pharmakern | Trandate</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Biascor</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Labever | Trandate</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Trandate</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Labetalol s.a.l.f | Trandate</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Trandate | Trantalol</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Trandate</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Trandate</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Avexa | Labesin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Trandate</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Trandate</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Abetol | Chenday | Labedin | Labenon | Labtal | Latol | Lavocohere | Presolol | Trandate | Tranmin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Labetalol</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Trandate</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Trandate</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36620804">
<a name="36620804"></a>Aiwuyo HO, Ilerhunmwuwa NP, Hakobyan N, et al. BRASH syndrome presenting with idioventricular escape rhythm in a patient with trifascicular block. <i>Cureus</i>. 2022;14(12):e32217. doi:10.7759/cureus.32217<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/36620804/pubmed" id="36620804" target="_blank">36620804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32443079">
<a name="32443079"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 222: Gestational hypertension and preeclampsia. <i>Obstet Gynecol</i>. 2020a;135(6):e237-e260. doi:10.1097/AOG.0000000000003891<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/32443079/pubmed" id="32443079" target="_blank">32443079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 203: chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50. doi: 10.1097/AOG.0000000000003020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACOG.1">
<a name="ACOG.1"></a>American College of Obstetricians and Gynecologists (ACOG). Severe hypertension in pregnancy bundle. Algorithm: labetalol. https://www.acog.org/-/media/project/acog/acogorg/files/forms/districts/smi-hypertension-bundle-labetalol-algorithm.pdf. Updated February 2020b. Accessed January 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>American Society of Health-System Pharmacists (ASHP). Adult continuous infusion standards. Available at https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Adult-Infusion-Standards.pdf. Updated September 2021a. Accessed June 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.2">
<a name="ASHP.2"></a>American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. Available at https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated January 2021b. Accessed January 7, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6184571">
<a name="6184571"></a>Anavekar SN, Barter C, Adam WR, Doyle AE. A double-blind comparison of verapamil and labetalol in hypertensive patients with coexisting chronic obstructive airways disease. <i>J Cardiovasc Pharmacol</i>. 1982;4 suppl 3:S374-S377.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/6184571/pubmed" id="6184571" target="_blank">6184571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28650212">
<a name="28650212"></a>Anderson PO. Choosing medication alternatives during breastfeeding, avoiding alternative facts. <i>Breastfeed Med</i>. 2017;12(6):328-330.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/28650212/pubmed" id="28650212" target="_blank">28650212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21518977">
<a name="21518977"></a>Aronow WS, Fleg JL, Pepine CJ, et al, “ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,” <i>Circulation</i>, 2011, 123(21):2434-506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/21518977/pubmed" id="21518977" target="_blank">21518977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.3">
<a name="ASHP.3"></a>ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-August.2022">
<a name="August.2022"></a>August P. Treatment of hypertension in pregnant and postpartum patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 6, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26362300">
<a name="26362300"></a>Axon RN, Turner M, Buckley R. An update on inpatient hypertension management. <i>Curr Cardiol Rep</i>. 2015;17(11):94. doi: 10.1007/s11886-015-0648-y.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/26362300/pubmed" id="26362300" target="_blank">26362300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15536109">
<a name="15536109"></a>Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. <i>JAMA</i>. 2004;292(18):2227-2236. doi:10.1001/jama.292.18.2227<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/15536109/pubmed" id="15536109" target="_blank">15536109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.1">
<a name="Expert.1"></a>Based on expert opinion.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bisognano.2019">
<a name="Bisognano.2019"></a>Bisognano JD. Perioperative management of hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 3, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Botros.1">
<a name="Botros.1"></a>Botros SM, Hussein AM, Elserafy AH. Effect of different beta blockers on penile vascular velocities in hypertensive males. <i>The Egyptian Journal of Radiology and Nuclear Medicine</i>. 2015;46(3):749-754. doi:10.1016/j.ejrnm.2015.04.004</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11790269">
<a name="11790269"></a>Bravo EL. Pheochromocytoma. <i>Cardiol Rev</i>. 2002;10(1):44-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/11790269/pubmed" id="11790269" target="_blank">11790269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17478736">
<a name="17478736"></a>Broderick J, Connolly S, Feldmann E, et al; American Heart Association; American Stroke Association Stroke Council; High Blood Pressure Research Council; Quality of Care and Outcomes in Research Interdisciplinary Working Group. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. <i>Stroke</i>. 2007;38(6):2001-2023. doi: 10.1161/STROKEAHA.107.183689.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/17478736/pubmed" id="17478736" target="_blank">17478736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brook.2020">
<a name="Brook.2020"></a>Brook RD, Townsend RR. Treatment of resistant hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1731011">
<a name="1731011"></a>Bunchman TE, Lynch RE, Wood EG. Intravenously administered labetalol for treatment of hypertension in children. <i>J Pediatr</i>. 1992;120(1):140-144.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/1731011/pubmed" id="1731011" target="_blank">1731011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29746858">
<a name="29746858"></a>Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. <i>J Urol</i>. 2018;200(3):633-641. doi:10.1016/j.juro.2018.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/29746858/pubmed" id="29746858" target="_blank">29746858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23535700">
<a name="23535700"></a>Cannon CM, Levy P, Baumann BM, et al. Intravenous nicardipine and labetalol use in hypertensive patients with signs or symptoms suggestive of end-organ damage in the emergency department: a subgroup analysis of the CLUE trial. <i>BMJ Open</i>. 2013;3(3). pii: e002338. doi: 10.1136/bmjopen-2012-002338.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/23535700/pubmed" id="23535700" target="_blank">23535700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. <i>Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22556195">
<a name="22556195"></a>Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al; American Heart Association Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2012;43(6):1711-1737. doi: 10.1161/STR.0b013e3182587839.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/22556195/pubmed" id="22556195" target="_blank">22556195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15579370">
<a name="15579370"></a>Covar RA, Macomber BA, Szefler SJ. Medications as asthma triggers. <i>Immunol Allergy Clin North Am</i>. 2005;25(1):169-190. doi:10.1016/j.iac.2004.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/15579370/pubmed" id="15579370" target="_blank">15579370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3009050">
<a name="3009050"></a>Croft CH, Rude RE, Gustafson N, et al. Abrupt withdrawal of beta-blockade therapy in patients with myocardial infarction: effects on infarct size, left ventricular function, and hospital course. <i>Circulation</i>. 1986;73(6):1281-1290. doi:10.1161/01.cir.73.6.1281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/3009050/pubmed" id="3009050" target="_blank">3009050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1969714">
<a name="1969714"></a>Dahlöf C, Dimenäs E. Side effects of beta-blocker treatments as related to the central nervous system. <i>Am J Med Sci</i>. 1990;299(4):236-244. doi:10.1097/00000441-199004000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/1969714/pubmed" id="1969714" target="_blank">1969714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31775749">
<a name="31775749"></a>Dungan K, Merrill J, Long C, Binkley P. Effect of beta blocker use and type on hypoglycemia risk among hospitalized insulin requiring patients. <i>Cardiovasc Diabetol</i>. 2019;18(1):163. doi:10.1186/s12933-019-0967-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/31775749/pubmed" id="31775749" target="_blank">31775749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2897781">
<a name="2897781"></a>Egstrup K. Transient myocardial ischemia after abrupt withdrawal of antianginal therapy in chronic stable angina. <i>Am J Cardiol</i>. 1988;61(15):1219-1222. doi:10.1016/0002-9149(88)91158-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/2897781/pubmed" id="2897781" target="_blank">2897781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Elliott.1">
<a name="Elliott.1"></a>Elliott WJ, Varon J. Drugs used for the treatment of hypertensive emergencies. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Elliott.2">
<a name="Elliott.2"></a>Elliott WJ, Varon J. Evaluation and treatment of hypertensive emergencies in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 7, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18505576">
<a name="18505576"></a>Fahed S, Grum DF, Papadimos TJ. Labetalol infusion for refractory hypertension causing severe hypotension and bradycardia: an issue of patient safety. <i>Patient Saf Surg</i>. 2008;2:13. doi: 10.1186/1754-9493-2-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/18505576/pubmed" id="18505576" target="_blank">18505576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33945044">
<a name="33945044"></a>Farmakis IT, Pyrgidis N, Doundoulakis I, Mykoniatis I, Akrivos E, Giannakoulas G. Effects of major antihypertensive drug classes on erectile function: a network meta-analysis. <i>Cardiovasc Drugs Ther</i>. 2021. doi:10.1007/s10557-021-07197-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/33945044/pubmed" id="33945044" target="_blank">33945044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956217">
<a name="20956217"></a>Field JM, Hazinski MF, Sayre MR, et al, “Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” <i>Circulation</i>, 2010, 122 (18 Suppl 3):640-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/20956217/pubmed" id="20956217" target="_blank">20956217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al, “2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,” <i>Circulation</i>, 2012, 126(25):3097-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28827377">
<a name="28827377"></a>Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2017;140(3):e20171904. doi:10.1542/peds.2017-1904<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/28827377/pubmed" id="28827377" target="_blank">28827377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18839219">
<a name="18839219"></a>Flynn JT, Tullus K. Severe hypertension in children and adolescents: pathophysiology and treatment [published correction appears in <i>Pediatr Nephrol</i>. 2012;27(3):503-504]. <i>Pediatr Nephrol</i>. 2009;24(6):1101-1112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/18839219/pubmed" id="18839219" target="_blank">18839219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18617067">
<a name="18617067"></a>Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. <i>J Am Coll Cardiol</i>. 2008;52(3):190-199. doi:10.1016/j.jacc.2008.03.048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/18617067/pubmed" id="18617067" target="_blank">18617067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20067434">
<a name="20067434"></a>Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. <i>Curr Med Res Opin</i>. 2010;26(3):615-629. doi:10.1185/03007990903533681<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/20067434/pubmed" id="20067434" target="_blank">20067434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2883874">
<a name="2883874"></a>Frishman WH. Beta-adrenergic blocker withdrawal. <i>Am J Cardiol</i>. 1987;59(13):26F-32F. doi:10.1016/0002-9149(87)90038-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/2883874/pubmed" id="2883874" target="_blank">2883874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2892986">
<a name="2892986"></a>Frishman WH. Beta-adrenergic blockers. <i>Med Clin North Am</i>. 1988;72(1):37-81. doi:10.1016/s0025-7125(16)30786-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/2892986/pubmed" id="2892986" target="_blank">2892986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3905285">
<a name="3905285"></a>George RB, Light RW, Hudson LD, et al. Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of hypertensive patients with asthma and propranolol sensitivity. <i>Chest</i>. 1985;88(6):815-818. doi:10.1378/chest.88.6.815<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/3905285/pubmed" id="3905285" target="_blank">3905285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6337786">
<a name="6337786"></a>George RB, Manocha K, Burford JG, Conrad SA, Kinasewitz GT. Effects of labetalol in hypertensive patients with chronic obstructive pulmonary disease. <i>Chest</i>. 1983;83(3):457-460. doi:10.1378/chest.83.3.457<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/6337786/pubmed" id="6337786" target="_blank">6337786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8956349">
<a name="8956349"></a>Gleiter CH, Deckert J. Adverse CNS-effects of beta-adrenoceptor blockers. <i>Pharmacopsychiatry</i>. 1996;29(6):201-211. doi:10.1055/s-2007-979572<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/8956349/pubmed" id="8956349" target="_blank">8956349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17534003">
<a name="17534003"></a>Gliebus G, Lippa CF. The influence of beta-blockers on delayed memory function in people with cognitive impairment. <i>Am J Alzheimers Dis Other Demen</i>. 2007;22(1):57-61. doi:10.1177/1533317506295889<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/17534003/pubmed" id="17534003" target="_blank">17534003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243703">
<a name="24243703"></a>Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/24243703/pubmed" id="24243703" target="_blank">24243703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2663413">
<a name="2663413"></a>Goa KL, Benfield P, Sorkin EM. Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease. <i>Drugs</i>. 1989;37(5):583-627.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/2663413/pubmed" id="2663413" target="_blank">2663413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2316229">
<a name="2316229"></a>Goldsmith TL, Barker DE, Strodel WE. Prolonged labetalol infusion for management of severe hypertension and tachycardia in a critically ill trauma patient. <i>DICP</i>. 1990;24(3):235-258. doi: 10.1177/106002809002400303<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/2316229/pubmed" id="2316229" target="_blank">2316229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35579034">
<a name="35579034"></a>Greenberg SM, Ziai WC, Cordonnier C, et al; American Heart Association/American Stroke Association. 2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2022;53(7):e282-e361. doi:10.1161/STR.0000000000000407<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/35579034/pubmed" id="35579034" target="_blank">35579034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7308279">
<a name="7308279"></a>Harley A, Coverdale HA. The electrophysiological effects of intravenous labetalol in man. <i>Eur J Clin Pharmacol</i>. 1981;20(4):241-244. doi:10.1007/BF00618772<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/7308279/pubmed" id="7308279" target="_blank">7308279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1244260">
<a name="1244260"></a>Harrison DC, Alderman EL. Editorial: Discontinuation of propranolol therapy. Cause of rebound angina pectoris and acute coronary events. <i>Chest</i>. 1976;69(1):1-2. doi:10.1378/chest.69.1.1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/1244260/pubmed" id="1244260" target="_blank">1244260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30753292">
<a name="30753292"></a>Hecht JP, Mahmood SM, Brandt MM. Safety of high-dose intravenous labetalol in hypertensive crisis. <i>Am J Health Syst Pharm</i>. 2019;76(5):286-292. doi:10.1093/ajhp/zxy045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/30753292/pubmed" id="30753292" target="_blank">30753292</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26022637">
<a name="26022637"></a>Hemphill JC 3rd, Greenberg SM, Anderson CS, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2015;46(7):2032-2060. doi: 10.1161/STR.0000000000000069.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/26022637/pubmed" id="26022637" target="_blank">26022637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29066880">
<a name="29066880"></a>Huang YL, Lai CC, Wang YH, et al. Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD. <i>Int J Chron Obstruct Pulmon Dis</i>. 2017;12:2987-2996. doi:10.2147/COPD.S145913<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/29066880/pubmed" id="29066880" target="_blank">29066880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3415804">
<a name="3415804"></a>Huey J, Thomas JP, Hendricks DR, Wehmeyer AE, Johns LJ, MacCosbe PE. Clinical evaluation of intravenous labetalol for the treatment of hypertensive urgency. <i>Am J Hypertens</i>. 1988;1(3, pt 3):284S-289S. doi: 10.1093/ajh/1.3.284s.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/3415804/pubmed" id="3415804" target="_blank">3415804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36322642">
<a name="36322642"></a>Isselbacher EM, Preventza O, Hamilton Black J 3rd, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American Heart Association/American College of Cardiology joint committee on clinical practice guidelines. <i>Circulation.</i> 2022;146(24):e334-e482. doi:10.1161/CIR.0000000000001106<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/36322642/pubmed" id="36322642" target="_blank">36322642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1977302">
<a name="1977302"></a>Jaillon P. Relevance of intrinsic sympathomimetic activity for beta blockers. <i>Am J Cardiol</i>. 1990;66(9):21C-23C. doi:10.1016/0002-9149(90)90758-s<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/1977302/pubmed" id="1977302" target="_blank">1977302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956227">
<a name="20956227"></a>Jauch EC, Cucchiara B, Adeoye O, et al, “Part 11: Adult Stroke: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” <i>Circulation</i>, 2010, 122(18 Suppl 3):818-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/20956227/pubmed" id="20956227" target="_blank">20956227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23370205">
<a name="23370205"></a>Jauch EC, Saver JL, Adams HP Jr, et al, “Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association,” <i>Stroke</i>, 2013, 44(3):870-947.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/23370205/pubmed" id="23370205" target="_blank">23370205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12117400">
<a name="12117400"></a>Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. <i>JAMA</i>. 2002;288(3):351-357. doi:10.1001/jama.288.3.351<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/12117400/pubmed" id="12117400" target="_blank">12117400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2865151">
<a name="2865151"></a>Koella WP. CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action. <i>Eur J Clin Pharmacol</i>. 1985;28 Suppl:55-63. doi:10.1007/BF00543711<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/2865151/pubmed" id="2865151" target="_blank">2865151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2878741">
<a name="2878741"></a>Kostis JB, Rosen RC. Central nervous system effects of beta-adrenergic-blocking drugs: the role of ancillary properties. <i>Circulation</i>. 1987;75(1):204-212. doi:10.1161/01.cir.75.1.204<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/2878741/pubmed" id="2878741" target="_blank">2878741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12490274">
<a name="12490274"></a>Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. <i>J Heart Lung Transplant</i>. 2002;21(12):1290-1295. doi:10.1016/s1053-2498(02)00459-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/12490274/pubmed" id="12490274" target="_blank">12490274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.1">
<a name="Hospira.1"></a>Labetalol Carpuject [prescribing information]. Lake Forest, IL: Hospira Inc; September 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hikma.1">
<a name="Hikma.1"></a>Labetalol injection [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Innogenix.1">
<a name="Innogenix.1"></a>Labetalol hydrochloride tablets (USP) [prescribing information]. Amityville, NY: Innogenix, LLC; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baxter.1">
<a name="Baxter.1"></a>Labetalol injection (USP) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-SteriMax.1">
<a name="SteriMax.1"></a>Labetalol injection (USP) [product monograph]. Oakville, Ontario, Canada: SteriMax Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sandoz.1">
<a name="Sandoz.1"></a>Labetalol tablets [prescribing information]. Princeton, NJ: Sandoz Inc; October 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-85053">
<a name="85053"></a>Lager I, Blohmé G, Smith U. Effect of cardioselective and non-selective beta-blockade on the hypoglycaemic response in insulin-dependent diabetics. <i>Lancet</i>. 1979;1(8114):458-462. doi:10.1016/s0140-6736(79)90821-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/85053/pubmed" id="85053" target="_blank">85053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2439802">
<a name="2439802"></a>Lammers JW, Folgering HT, van Herwaarden CL. Respiratory tolerance of bisoprolol and metoprolol in asthmatic patients. <i>J Cardiovasc Pharmacol</i>. 1986;8 suppl 11:S69-S73. doi:10.1097/00005344-198511001-00012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/2439802/pubmed" id="2439802" target="_blank">2439802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37093">
<a name="37093"></a>Lederballe Pedersen O, Mikkelsen E, Lanng Nielsen J, Christensen NJ. Abrupt withdrawal of beta-blocking agents in patients with arterial hypertension. Effect on blood pressure, heart rate and plasma catecholamines and prolactin. <i>Eur J Clin Pharmacol</i>. 1979;15(3):215-217. doi:10.1007/BF00563108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/37093/pubmed" id="37093" target="_blank">37093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22267844">
<a name="22267844"></a>Levine GN, Steinke EE, Bakaeen FG, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Quality of Care and Outcomes Research. Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2012;125(8):1058-1072. doi: 10.1161/CIR.0b013e3182447787<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/22267844/pubmed" id="22267844" target="_blank">22267844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22864917">
<a name="22864917"></a>Lien SF, Bisognano JD. Perioperative hypertension: defining at-risk patients and their management. <i>Curr Hypertens Rep</i>. 2012;14(5):432-441. doi: 10.1007/s11906-012-0287-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/22864917/pubmed" id="22864917" target="_blank">22864917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27390282">
<a name="27390282"></a>Lipworth B, Wedzicha J, Devereux G, Vestbo J, Dransfield MT. Beta-blockers in COPD: time for reappraisal. <i>Eur Respir J</i>. 2016;48(3):880-888. doi:10.1183/13993003.01847-2015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/27390282/pubmed" id="27390282" target="_blank">27390282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18250979">
<a name="18250979"></a>Liu-DeRyke X, Janisse J, Coplin WM, Parker D Jr, Norris G, Rhoney DH. A comparison of nicardipine and labetalol for acute hypertension management following stroke. <i>Neurocrit Care</i>. 2008;9(2):167-176.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/18250979/pubmed" id="18250979" target="_blank">18250979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23760911">
<a name="23760911"></a>Liu-DeRyke X, Levy PD, Parker D Jr, Coplin W, Rhoney DH. A prospective evaluation of labetalol versus nicardipine for blood pressure management in patients with acute stroke. <i>Neurocrit Care</i>. 2013;19(1):41-47. doi: 10.1007/s12028-013-9863-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/23760911/pubmed" id="23760911" target="_blank">23760911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-London.2022">
<a name="London.2022"></a>London MJ. Hemodynamic management during anesthesia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15288162">
<a name="15288162"></a>López-Sendón J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. <i>Eur Heart J</i>. 2004;25(15):1341-1362. doi:10.1016/j.ehj.2004.06.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/15288162/pubmed" id="15288162" target="_blank">15288162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27899939">
<a name="27899939"></a>Lu HT, Kam J, Nordin RB, et al. Beta-blocker use and risk of symptomatic bradyarrhythmias: a hospital-based case-control study. <i>J Geriatr Cardiol</i>. 2016;13(9):749-759. doi:10.11909/j.issn.1671-5411.2016.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/27899939/pubmed" id="27899939" target="_blank">27899939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4043203">
<a name="4043203"></a>Lunell NO, Kulas J, and Rane A, "Transfer of Labetalol Into Amniotic Fluid and Breast Milk in Lactating Women," <i>Eur J Clin Pharmacol</i>, 1985, 28(5):597-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/4043203/pubmed" id="4043203" target="_blank">4043203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6310529">
<a name="6310529"></a>MacCarthy EP, Bloomfield SS. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. <i>Pharmacotherapy</i>. 1983;3(4):193-219. doi: 10.1002/j.1875-9114.1983.tb03252.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/6310529/pubmed" id="6310529" target="_blank">6310529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline No. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management.<i> J Obstet Gynaecol Can.</i> 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22300487">
<a name="22300487"></a>Malesker MA, Hilleman DE. Intravenous labetalol compared with intravenous nicardipine in the management of hypertension in critically ill patients. <i>J Crit Care</i>. 2012;27(5):528.e7-528.e14. doi:10.1016/j.jcrc.2011.12.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/22300487/pubmed" id="22300487" target="_blank">22300487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11821644">
<a name="11821644"></a>Manger WM, Gifford RW. Pheochromocytoma. <i>J Clin Hypertens (Greenwich)</i>. 2002;4(1):62-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/11821644/pubmed" id="11821644" target="_blank">11821644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.2020">
<a name="Mann.2020"></a>Mann SJ. Paroxysmal hypertension (pseudopheochromocytoma). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 5, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21986463">
<a name="21986463"></a>Marik PE, Rivera R. Hypertensive emergencies: an update. <i>Curr Opin Crit Care</i>. 2011;17(6):569-580. doi: 10.1097/MCC.0b013e32834cd31d.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/21986463/pubmed" id="21986463" target="_blank">21986463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17565029">
<a name="17565029"></a>Marik PE, Varon J. Hypertensive crises: challenges and management. <i>Chest. </i>2007;131(6);1949-1962. doi: 10.1378/chest.06-2490.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/17565029/pubmed" id="17565029" target="_blank">17565029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23817839">
<a name="23817839"></a>Mazza A, Armigliato M, Marzola MC, et al. Anti-hypertensive treatment in pheochromocytoma and paraganglioma: current management and therapeutic features. <i>Endocrine</i>. 2014;45(3):469-478.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/23817839/pubmed" id="23817839" target="_blank">23817839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1969642">
<a name="1969642"></a>McAinsh J, Cruickshank JM. Beta-blockers and central nervous system side effects. <i>Pharmacol Ther</i>. 1990;46(2):163-197. doi:10.1016/0163-7258(90)90092-g<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/1969642/pubmed" id="1969642" target="_blank">1969642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6370541">
<a name="6370541"></a>McNeil JJ, Louis WJ. Clinical pharmacokinetics of labetalol. <i>Clin Pharmacokinet</i>. 1984;9(2):157-167.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/6370541/pubmed" id="6370541" target="_blank">6370541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26635169">
<a name="26635169"></a>Michael CA. Use of labetalol in the treatment of severe hypertension during pregnancy. <i>Br J Clin Pharmacol</i>. 1979;8(Suppl 2):211S-215S. doi: 10.1111/j.1365-2125.1979.tb04783.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/26635169/pubmed" id="26635169" target="_blank">26635169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2861072">
<a name="2861072"></a>Mills GA, Horn JR. Beta-blockers and glucose control. <i>Drug Intell Clin Pharm</i>. 1985;19(4):246-251. doi:10.1177/106002808501900401<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/2861072/pubmed" id="2861072" target="_blank">2861072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mirpuri.2008">
<a name="Mirpuri.2008"></a>Mirpuri J, Patel H, Rhee D, et al. AFMR Southern Regional Meeting Abstracts. What's mom on? A case of bradycardia in a premature infant on breast milk. <i>J Investig Med</i>. 2008;56(1):409.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17967691">
<a name="17967691"></a>Mocco J, Rose JC, Komotar RJ, Mayer SA. Blood pressure management in patients with intracerebral and subarachnoid hemorrhage. <i>Neurosurg Clin N Am</i>. 2006;17(suppl 1):25-40. doi: 10.1016/s1042-3680(06)80005-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/17967691/pubmed" id="17967691" target="_blank">17967691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24202435">
<a name="24202435"></a>Morales DR, Jackson C, Lipworth BJ, Donnan PT, Guthrie B. Adverse respiratory effect of acute β-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials. <i>Chest</i>. 2014;145(4):779-786. doi:10.1378/chest.13-1235<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/24202435/pubmed" id="24202435" target="_blank">24202435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34739303">
<a name="34739303"></a>Mulrenin IR, Garcia JE, Fashe MM, et al. The impact of pregnancy on antihypertensive drug metabolism and pharmacokinetics: current status and future directions. <i>Expert Opin Drug Metab Toxicol</i>. 2021;17(11):1261-1279. doi:10.1080/17425255.2021.2002845<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/34739303/pubmed" id="34739303" target="_blank">34739303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NHLBI.1">
<a name="NHLBI.1"></a>National Heart, Lung, and Blood Institute (NHLBI). Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Full Report. Clinical Practice Guidelines, 2012, National Institutes of Health. <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>. Accessed May 31, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management. NICE guideline, No. 133. http://www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24155101">
<a name="24155101"></a>Nicolai MP, Liem SS, Both S, et al. A review of the positive and negative effects of cardiovascular drugs on sexual function: a proposed table for use in clinical practice. <i>Neth Heart J</i>. 2014;22(1):11-19. doi:10.1007/s12471-013-0482-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/24155101/pubmed" id="24155101" target="_blank">24155101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24589852">
<a name="24589852"></a>Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/24589852/pubmed" id="24589852" target="_blank">24589852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3339748">
<a name="3339748"></a>O'Meara J, White WB. Ejaculatory failure and urinary dysfunction secondary to labetalol. <i>J Urol</i>. 1988;139(2):371-372. doi:10.1016/s0022-5347(17)42420-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/3339748/pubmed" id="3339748" target="_blank">3339748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23055089">
<a name="23055089"></a>Ortega-Gutierrez S, Thomas J, Reccius A, et al. Effectiveness and safety of nicardipine and labetalol infusion for blood pressure management in patients with intracerebral and subarachnoid hemorrhage. <i>Neurocrit Care</i>. 2013;18(1):13-9. doi: 10.1007/s12028-012-9782-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/23055089/pubmed" id="23055089" target="_blank">23055089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22530749">
<a name="22530749"></a>Osmonov D, Erdinler I, Ozcan KS, et al. Management of patients with drug-induced atrioventricular block. <i>Pacing Clin Electrophysiol</i>. 2012;35(7):804-810. doi:10.1111/j.1540-8159.2012.03410.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/22530749/pubmed" id="22530749" target="_blank">22530749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7116758">
<a name="7116758"></a>Papademetriou V, Notargiacomo AV, Khatri IM, Freis ED. Treatment of severe hypertension with intravenous labetalol. <i>Clin Pharmacol Ther</i>. 1982;32(4):431-435. doi: 10.1038/clpt.1982.185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/7116758/pubmed" id="7116758" target="_blank">7116758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8439694">
<a name="8439694"></a>Patel RV, Kertland HR, Jahns BE, Zarowitz BJ, Mlynarek ME, Fagan SC. Labetalol: response and safety in critically ill hemorrhagic stroke patients. <i>Ann Pharmacother</i>. 1993;27(2):180-181. doi: 10.1177/106002809302700209.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/8439694/pubmed" id="8439694" target="_blank">8439694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21908132">
<a name="21908132"></a>Peacock WF 4th, Hilleman DE, Levy PD, Rhoney DH, Varon J. A systematic review of nicardipine vs labetalol for the management of hypertensive crises. <i>Am J Emerg Med</i>. 2012;30(6):981-993. doi: 10.1016/j.ajem.2011.06.040.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/21908132/pubmed" id="21908132" target="_blank">21908132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31693807">
<a name="31693807"></a>Peixoto AJ. Acute severe hypertension. <i>N Engl J Med</i>. 2019;381(19):1843-1852. doi: 10.1056/NEJMcp1901117.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/31693807/pubmed" id="31693807" target="_blank">31693807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28840400">
<a name="28840400"></a>Petta V, Perlikos F, Loukides S, et al. Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease. <i>Heart Fail Rev</i>. 2017;22(6):753-763. doi:10.1007/s10741-017-9646-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/28840400/pubmed" id="28840400" target="_blank">28840400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6376017">
<a name="6376017"></a>Popp DA, Tse TF, Shah SD, Clutter WE, Cryer PE. Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus. <i>Diabetes Care</i>. 1984;7(3):243-247. doi:10.2337/diacare.7.3.243<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/6376017/pubmed" id="6376017" target="_blank">6376017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31662037">
<a name="31662037"></a>Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2019;50(12):e344-e418. doi:10.1161/STR.0000000000000211<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/31662037/pubmed" id="31662037" target="_blank">31662037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6125186">
<a name="6125186"></a>Prichard BN, Walden RJ. The syndrome associated with the withdrawal of beta-adrenergic receptor blocking drugs. <i>Br J Clin Pharmacol</i>. 1982;13(suppl 2):337S-343S. doi:10.1111/j.1365-2125.1982.tb01938.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/6125186/pubmed" id="6125186" target="_blank">6125186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2450898">
<a name="2450898"></a>Prystowsky EN. The effects of slow channel blockers and beta blockers on atrioventricular nodal conduction. <i>J Clin Pharmacol</i>. 1988;28(1):6-21. doi:10.1002/j.1552-4604.1988.tb03095.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/2450898/pubmed" id="2450898" target="_blank">2450898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1968518">
<a name="1968518"></a>Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui TS. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. <i>JAMA</i>. 1990;263(12):1653-1657.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/1968518/pubmed" id="1968518" target="_blank">1968518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6125187">
<a name="6125187"></a>Rangno RE, Langlois S. Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol. <i>Br J Clin Pharmacol</i>. 1982;13(suppl 2):345S-351S. doi:10.1111/j.1365-2125.1982.tb01939.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/6125187/pubmed" id="6125187" target="_blank">6125187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6608433">
<a name="6608433"></a>Reder RF, Mindich B, Halperin J, Litwak RS, Kupersmith J. Acute effects of oral labetalol on myocardial conduction after coronary artery bypass grafting. <i>Clin Pharmacol Ther</i>. 1984;35(4):454-460. doi:10.1038/clpt.1984.59<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/6608433/pubmed" id="6608433" target="_blank">6608433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19724774">
<a name="19724774"></a>Rogers D, Pies R. General medical with depression drugs associated. <i>Psychiatry (Edgmont)</i>. 2008;5(12):28-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/19724774/pubmed" id="19724774" target="_blank">19724774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25445109">
<a name="25445109"></a>Rolfes L, de Swart-Ruijter I, van Hunsel F. Labetalol for hypertension during pregnancy and nipple pain. <i>Eur J Obstet Gynecol Reprod Biol</i>. 2014;182:254-255.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/25445109/pubmed" id="25445109" target="_blank">25445109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rordorf.2022">
<a name="Rordorf.2022"></a>Rordorf G, McDonald C. Spontaneous intracerebral hemorrhage: Acute treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16174926">
<a name="16174926"></a>Rose JC, Mayer SA. Optimizing blood pressure in neurological emergencies [published correction appears in <i>Neurocrit Care</i>. 2006;4(1):98]. <i>Neurocrit Care</i>. 2004;1(3):287-299. doi: 10.1385/NCC:1:3:287.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/16174926/pubmed" id="16174926" target="_blank">16174926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8227470">
<a name="8227470"></a>Saotome T, Minoura S, Terashi K, Sato T, Echizen H, Ishizaki T. Labetalol in hypertension during the third trimester of pregnancy: its antihypertensive effect and pharmacokinetic-dynamic analysis. <i>J Clin Pharmacol</i>. 1993;33(10):979-988. doi: 10.1002/j.1552-4604.1993.tb01933.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/8227470/pubmed" id="8227470" target="_blank">8227470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22667825">
<a name="22667825"></a>Sarafidis PA, Georgianos PI, Malindretos P, Liakopoulos V. Pharmacological management of hypertensive emergencies and urgencies: focus on newer agents. <i>Expert Opin Investig Drugs</i>. 2012;21(8):1089-1106. doi: 10.1517/13543784.2012.693477.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/22667825/pubmed" id="22667825" target="_blank">22667825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23024438">
<a name="23024438"></a>Scheer FA, Morris CJ, Garcia JI, et al. Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial. <i>Sleep</i>. 2012;35(10):1395-1402. doi:10.5665/sleep.2122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/23024438/pubmed" id="23024438" target="_blank">23024438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28622464">
<a name="28622464"></a>Semet M, Paci M, Saïas-Magnan J, et al. The impact of drugs on male fertility: a review. <i>Andrology</i>. 2017;5(4):640-663. doi:10.1111/andr.12366<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/28622464/pubmed" id="28622464" target="_blank">28622464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-668066">
<a name="668066"></a>Shand DG, Wood AJ. Propranolol withdrawal syndrome - why? <i>Circulation</i>. 1978;58(2):202-203. doi:10.1161/01.cir.58.2.202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/668066/pubmed" id="668066" target="_blank">668066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9207336">
<a name="9207336"></a>Shorr RI, Ray WA, Daugherty JR, Griffin MR. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. <i>JAMA</i>. 1997;278(1):40-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/9207336/pubmed" id="9207336" target="_blank">9207336</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Singer.2022">
<a name="Singer.2022"></a>Singer RJ, Ogilvy CS, Rordorf G. Aneurysmal subarachnoid hemorrhage: Treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31705851">
<a name="31705851"></a>Stanistreet B, Nicholas JA, Bisognano JD. An evidence-based review of elevated blood pressure for the inpatient. <i>Am J Med</i>. 2020;133(2):165-169. doi: 10.1016/j.amjmed.2019.10.004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/31705851/pubmed" id="31705851" target="_blank">31705851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34331033">
<a name="34331033"></a>Terentes-Printzios D, Ioakeimidis N, Rokkas K, Vlachopoulos C. Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs. <i>Nat Rev Cardiol</i>. 2022;19(1):59-74. doi:10.1038/s41569-021-00593-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/34331033/pubmed" id="34331033" target="_blank">34331033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20495503">
<a name="20495503"></a>Thomas CA, Moffett BS, Wagner JL, et al. Safety and efficacy of intravenous labetalol for hypertensive crisis in infants and small children. <i>Pediatr Crit Care Med</i>, 2011;12(1):28-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/20495503/pubmed" id="20495503" target="_blank">20495503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31352857">
<a name="31352857"></a>Tiotiu A, Novakova P, Kowal K, et al. Beta-blockers in asthma: myth and reality. <i>Expert Rev Respir Med</i>. 2019;13(9):815-822. doi:10.1080/17476348.2019.1649147<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/31352857/pubmed" id="31352857" target="_blank">31352857</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Trandate.1">
<a name="Trandate.1"></a>Trandate (labetalol) [prescribing information]. San Diego, CA: Prometheus Laboratories Inc; November 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28559400">
<a name="28559400"></a>Tsujimoto T, Sugiyama T, Shapiro MF, Noda M, Kajio H. Risk of cardiovascular events in patients with diabetes mellitus on β-blockers. <i>Hypertension</i>. 2017;70(1):103-110. doi:10.1161/HYPERTENSIONAHA.117.09259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/28559400/pubmed" id="28559400" target="_blank">28559400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36104450">
<a name="36104450"></a>van de Vusse D, Mian P, Schoenmakers S, et al. Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review. <i>Eur J Clin Pharmacol.</i> 2022;78(11):1763-1776. doi:10.1007/s00228-022-03382-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/36104450/pubmed" id="36104450" target="_blank">36104450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Varon.2019">
<a name="Varon.2019"></a>Varon J, Elliot WJ. Management of severe asymptomatic hypertension (hypertensive urgencies) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 11, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32073535">
<a name="32073535"></a>Viigimaa M, Vlachopoulos C, Doumas M, et al; European Society of Hypertension Working Group on Sexual Dysfunction. Update of the position paper on arterial hypertension and erectile dysfunction. <i>J Hypertens</i>. 2020;38(7):1220-1234. doi:10.1097/HJH.0000000000002382<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/32073535/pubmed" id="32073535" target="_blank">32073535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vue.1">
<a name="Vue.1"></a>Vue MH, Setter SM. Drug-induced glucose alterations part 1: drug-induced hypoglycemia. <i>Diabetes Spectr</i>. 2011;24(3):171-177. doi:10.2337/diaspect.24.3.171</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6961760">
<a name="6961760"></a>Walstad RA, Berg KJ, Wessel-Aas T, Nilsen OG. Labetalol in the treatment of hypertension in patients with normal and impaired renal function. <i>Acta Med Scand Suppl</i>. 1982;665:135-141. doi:10.1111/j.0954-6820.1982.tb00423.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/6961760/pubmed" id="6961760" target="_blank">6961760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20579773">
<a name="20579773"></a>Wang J, Ono K, Dickstein DL, et al. Carvedilol as a potential novel agent for the treatment of Alzheimer's disease. <i>Neurobiol Aging</i>. 2011;32(12):2321.e1-2321.e23212. doi:10.1016/j.neurobiolaging.2010.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/20579773/pubmed" id="20579773" target="_blank">20579773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2865153">
<a name="2865153"></a>Westerlund A. Central nervous system side-effects with hydrophilic and lipophilic beta-blockers. <i>Eur J Clin Pharmacol</i>. 1985;28 suppl:73-76. doi:10.1007/BF00543714<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/2865153/pubmed" id="2865153" target="_blank">2865153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. <i>Hypertension</i>. 2018;71(6):e13-e115. doi:10.1161/HYP.0000000000000065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2206162">
<a name="2206162"></a>Willis JK, Tilton AH, Harkin JC, et al, "Reversible Myopathy Due to Labetalol," <i>Pediatr Neurol</i>, 1990, 6(4):275-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/2206162/pubmed" id="2206162" target="_blank">2206162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22528277">
<a name="22528277"></a>Woloszyn AV, McAllen KJ, Figueroa BE, DeShane RS, Barletta JF. Retrospective evaluation of nicardipine versus labetalol for blood pressure control in aneurysmal subarachnoid hemorrhage. <i>Neurocrit Care</i>. 2012;16(3):376-380. doi: 10.1007/s12028-012-9700-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/22528277/pubmed" id="22528277" target="_blank">22528277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7093103">
<a name="7093103"></a>Wood AJ, Ferry DG, Bailey RR. Elimination kinetics of labetalol in severe renal failure. <i>Br J Clin Pharmacol</i>. 1982;13(suppl 1):S81-S86. doi:10.1111/j.1365-2125.1982.tb01893.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/7093103/pubmed" id="7093103" target="_blank">7093103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3723159">
<a name="3723159"></a>Wright JT Jr, Wilson DJ, Goodman RP, Minisi AJ. Labetalol by continuous intravenous infusion in severe hypertension. <i>J Clin Hypertens</i>. 1986;2(1):39-43<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/3723159/pubmed" id="3723159" target="_blank">3723159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6869384">
<a name="6869384"></a>Yuen PH, Taddei CR, Wyka BE, Chaudry IA. Compatibility and stability of labetalol hydrochloride in commonly used intravenous solutions. <i>Am J Hosp Pharm</i>. 1983;40(6):1007-1009.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/6869384/pubmed" id="6869384" target="_blank">6869384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15234417">
<a name="15234417"></a>Zeltser D, Justo D, Halkin A, et al. Drug-induced atrioventricular block: prognosis after discontinuation of the culprit drug. <i>J Am Coll Cardiol</i>. 2004;44(1):105-108. doi:10.1016/j.jacc.2004.03.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/15234417/pubmed" id="15234417" target="_blank">15234417</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9540 Version 626.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
